Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 4/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | GCLC | P48506 | 2/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4756185 | 1.00 | SLC1A3 (0.52) | SLC1A3SLC1A2SLC1A1CA2MAPK1 | |
| SCHEMBL16683908 | 1.00 | SLC1A3 (0.52) | SLC1A3SLC1A2SLC1A1CA2MAPK1 | |
| SCHEMBL3833965 | 0.82 | CA2 (0.54) | SLC1A3SLC1A2SLC1A1CA2MAPK1 | |
| SCHEMBL27809820 | 0.81 | CHRM1 (0.65) | SLC1A3SLC1A2SLC1A1CA2MAPK1 | |
| SCHEMBL21017198 | 0.81 | CHRM1 (0.65) | SLC1A3SLC1A2SLC1A1CA2MAPK1 | |
| SCHEMBL19192783 | 0.80 | CA2 (0.41) | SLC1A3SLC1A2SLC1A1CA2MAPK1 | |
| SCHEMBL26838933 | 0.79 | FOLH1 (0.54) | SLC1A3SLC1A2SLC1A1CA2MAPK1 | |
| SCHEMBL61510 | 0.79 | FOLH1 (0.54) | SLC1A3SLC1A2SLC1A1CA2MAPK1 | |
| Hydroxyamine SCHEMBL4703121 | 0.78 | CA2 (0.64) | SLC1A3SLC1A2SLC1A1CA2MAPK1 | |
| Methylamine SCHEMBL27900431 | 0.78 | CA2 (0.64) | SLC1A3SLC1A2SLC1A1CA2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | disclosed |
| WO-2008155619-A2 | PREPARATION OF OPTICALLY-ACTIVE CYCLIC AMINO ACIDS | PFIZER INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | GRIN1, GRIN3A, GRIN2C | SLC1A3 86/4885SLC1A2 41/4885SLC1A1 62/4885 |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | SLC1A3 1037/4885SLC1A2 1100/4885SLC1A1 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.